It’s time to think differently about
diarrhea and its treatment in patients
living with HIV.Mytesi is indicated for symptomatic relief of
noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy.Restore. Relief.Discover Mytesi

Restore. Relief.

It’s time to think differently about diarrhea and its treatment in patients living with HIV.

Mytesi is indicated for symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

Group of people image.
Pipeline Icon

You are not alone.

1 in 4 people living with HIV experience chronic diarrhea.1,2 Get educated—and empowered.

Group of people image.
1 in 4 icon

You are not alone.

1 in 4 people living with HIV experience chronic diarrhea.1,2 Get educated—and empowered.

Pipeline Icon

Relief is possible.

After 20 weeks of Mytesi treatment, 9 out of 10 adults living with HIV had fewer watery stools—and over half had NO watery stools.3

Image of smiling woman
Image of smiling woman

Relief is possible.

After 20 weeks of Mytesi treatment, 9 out of 10 adults living with HIV had fewer watery stools—and over half had NO watery stools.3

Mytesi Product image

Save on Mytesi.

Pay as little as $0 for your Mytesi prescription (for eligible commercially insured patients, restrictions may apply).

Receive comprehensive support designed for you.

Mytesi Product Image

Save on Mytesi.

Pay as little as $0 for your Mytesi prescription (for eligible commercially insured patients, restrictions may apply).

Receive comprehensive support designed for you.

From tree to treatment.

The active ingredient in Mytesi comes from nature. Our reforestation programs are dedicated to supporting local and Indigenous communities and maintaining the integrity of the surrounding environment.

Tree Graphic
Use our guide to help discuss your symptoms with your doctor and to find out if Mytesi is right for you.
Use our guide to help discuss your symptoms with your doctor and to find out if Mytesi is right for you.

References: 1. Gehrig M, Clay P, Perry R, et al. Actual versus perceived use of pharmacokinetic (primarily absorption) influential OTC agents and ART tolerability in a nationwide matched cohort of HIV patients and their healthcare providers. Presented at: ID Week 2016; October 28, 2016; New Orleans, LA. Abstract 1514. 2. Castro JG, Chin-Beckford N. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Expert Rev Clin Pharmacol. 2015;8(6):683-690. doi:10.1586/17512433.2015.1082424 3. MacArthur RD, Clay P, Blick G, et al. Long-Term Crofelemer Provides Clinically Relevant Reductions in HIV-Related Diarrhea. Poster presented at: 9th IAS Conference on HIV Science (IAS 2017); July 23-26, 2017; Paris, France.